Cytokines and signal transduction

被引：78

作者：

Hideshima, T ^{[1
]}

Podar, K ^{[1
]}

Chauhan, D ^{[1
]}

Anderson, KC ^{[1
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2005年 / 18卷 / 04期

关键词：

multiple myeloma; cytokine; signal transduction; bone marrow;

D O I：

10.1016/j.beha.2005.01.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Many studies have characterized the role of growth factors in multiple myeloma (MM) pathogenesis and have derived novel therapies to improve patient outcome based upon targeting cytokines and their signaling cascades both in the MM cell and in the bone-marrow (BM) microenvironment. These cytokines include interleukin 6 (IL-6), insulin-like growth factor I (IGF-1), vascular endothelial growth factor (VEGF), tumor necrosis factor alpha (TNF-alpha), transforming growth factor beta (TGF-beta), stromal cell-derived factor I alpha (SDF-I alpha), IL-21, B-cell stimulating factor 3 (BSF-3) and fibroblast growth factor (FGF). These cytokines are secreted from stromal cells (SCs), endothelial cells and/or osteoclasts, and promote MM cell growth, survival and migration, as well as paracrine cytokine secretion and angiogenesis in the BM milieu. Thus inhibition of signaling cascades induced by these cytokine provides rationale for a therapeutic option for MM.

引用

页码：509 / 524

页数：16

共 147 条

[1] Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma [J].

Abe, M ;

Hiura, K ;

Wilde, J ;

Moriyama, K ;

Hashimoto, T ;

Ozaki, S ;

Wakatsuki, S ;

Kosaka, M ;

Kido, S ;

Inoue, D ;

Matsumoto, T .

BLOOD, 2002, 100 (06) :2195-2202

[2] Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I that highly express IL-6 receptor α myeloma cells [J].

Abroun, S ;

Ishikawa, H ;

Tsuyama, N ;

Liu, SQ ;

Li, FJ ;

Otsuyama, K ;

Zheng, X ;

Obata, M ;

Kawano, MM .

BLOOD, 2004, 103 (06) :2291-2298

[3]

Akiyama M, 2003, CANCER RES, V63, P18

[4]

Akiyama M, 2002, CANCER RES, V62, P3876

[5] The NF-kappa B and I kappa B proteins: New discoveries and insights [J].

Baldwin, AS .

ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683

[6] SERUM LEVELS OF INTERLEUKIN-6, A POTENT MYELOMA CELL-GROWTH FACTOR, AS A REFLECT OF DISEASE SEVERITY IN PLASMA-CELL DYSCRASIAS [J].

BATAILLE, R ;

JOURDAN, M ;

ZHANG, XG ;

KLEIN, B .

JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (06) :2008-2011

[7] THE I-KAPPA-B PROTEINS - MULTIFUNCTIONAL REGULATORS OF REL/NF-KAPPA-B TRANSCRIPTION FACTORS [J].

BEG, AA ;

BALDWIN, AS .

GENES & DEVELOPMENT, 1993, 7 (11) :2064-2070

[8] HHV-8 is present in multiple myeloma patients [J].

Berenson, JR ;

Vescio, RA .

BLOOD, 1999, 93 (10) :3157-3159

[9] Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma [J].

Bisping, G ;

Leo, R ;

Wenning, D ;

Dankbar, B ;

Padró, T ;

Kropff, M ;

Scheffold, C ;

Kröger, M ;

Mesters, RM ;

Berdel, WE ;

Kienast, J .

BLOOD, 2003, 101 (07) :2775-2783

[10] Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma [J].

Brander, C ;

Raje, N ;

O'Connor, PG ;

Davies, F ;

Davis, J ;

Chauhan, D ;

Hideshima, T ;

Martin, J ;

Osmond, D ;

Kedes, DH ;

Walker, BD ;

Scadden, DT ;

Anderson, KC .

BLOOD, 2002, 100 (02) :698-700

← 1 2 3 4 5 6 7 8 9 10 →